Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney ...
USAA's banking arm has grown its customer base for years, all while failing to make the investments needed to keep both its regulators and some decades-long customers happy ... "While I realize ...
There is an urgent need for governments and regulators to provide more effective ... contracting practices had transformed traditional work arrangements, creating challenges for workforce ...
A new study found that prolonged standing at work had a negative impact on the research participants' 24-hour blood pressure. In contrast, spending more time sitting at work was associated with ...